Faculty of Medicine Universitas Indonesia - Dr Cipto Mangunkusumo Hospital Report issue

Academic/Hospital Phase 2 Phase 3

Organization Overview

First Clinical Trial
2018
NCT04418089
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Department of Pathology, Dr. Cipto Mangunkusumo General Hospital, Jakarta, Indonesia | Department of Surgery, Dr. Cipto Mangunkusumo General Hospital, Jakarta, Indonesia | Faculty of Medicine Universitas Indonesia - Dr Cipto Mangunkusumo Hospital | Faculty of Medicine University of Indonesia Cipto Mangunkusumo Hospital | Internship Program as Research Assistant, Department of Surgery, Dr. Cipto Mangunkusumo General Hospital, Jakarta, Indonesia

Active Ingredients

Drugs in Phase 3 Trials (1)

COVID-19 convalescent plasma (1 trial)

Drugs in Phase 2 Trials (1)

simvastatin (zocor) (1 trial)

Drugs in Other Trials (2)

docosahexaenoic acid (1 trial)

fish oil (Omegavan) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acute Lung Injury (Phase 3)

Breast Neoplasms (Phase 2)

Respiratory Distress Syndrome (Phase 3)

Respiratory Distress Syndrome, Newborn (Phase 3)

Syndrome (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 3
  • # of Trial APIs: 4